Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PC-SOD for prevention of chemotherapy-induced peripheral neuropathy in colorectal cancer patients receiving mFOLFOX
jRCT2041250081Phase 3Recruiting
- Sponsor
- LTT Bio-Pharma Co., Ltd.
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing PC-SOD arm with Placebo arm (2 arms). Primary endpoint: Time to onset of grade 2 or higher chemotherapy-induced peripheral neuropathy. Started Aug 2025; status: recruiting.
02
Drugs
lecithinized superoxide dismutase
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on jRCT2041250081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250081.